Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AEMD

AEMD - Aethlon Medical Inc Stock Price, Fair Value and News

0.59USD0.00 (0.00%)Market Closed

Market Summary

AEMD
USD0.590.00
Market Closed
0.00%

AEMD Stock Price

View Fullscreen

AEMD RSI Chart

AEMD Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

0.41

Price/Free Cashflow

-0.14

AEMD Price/Sales (Trailing)

AEMD Profitability

Return on Equity

-160.94%

Return on Assets

-117.37%

Free Cashflow Yield

-696.51%

AEMD Fundamentals

AEMD Revenue

Revenue (TTM)

3.7M

Rev. Growth (Yr)

-8.37%

Rev. Growth (Qtr)

-41%

AEMD Earnings

Earnings (TTM)

-12.2M

Earnings Growth (Yr)

-21.63%

Earnings Growth (Qtr)

-14.23%

Breaking Down AEMD Revenue

Last 7 days

-14.5%

Last 30 days

37.2%

Last 90 days

-65.5%

Trailing 12 Months

-84.5%

How does AEMD drawdown profile look like?

AEMD Financial Health

Current Ratio

3.93

AEMD Investor Care

Shares Dilution (1Y)

14.08%

Diluted EPS (TTM)

-4.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.5M3.7M3.8M3.7M
20222.6M2.9M3.2M3.5M
20212.6M2.7M2.6M2.5M
20202.7M2.7M2.6M2.6M
20192.2M2.3M2.7M2.7M
20181.9M2.0M2.0M2.6M
20172.2M1.9M1.8M1.5M
20162.3M2.3M2.4M2.4M
20151.6M1.7M1.8M2.1M
20141.6M1.7M1.7M1.2M
20131.9M1.7M1.6M1.7M
20121.6M1.7M1.9M1.9M
20111.1M1.3M1.2M1.3M
20100000

Tracking the Latest Insider Buys and Sells of Aethlon Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 16, 2024
gikakis nicolas
acquired
49,998
1.52
32,894
-
Apr 16, 2024
rossetti angela
acquired
49,998
1.52
32,894
-
Apr 16, 2024
shah chetan
acquired
49,998
1.52
32,894
-
Apr 16, 2024
broenniman edward g
acquired
49,998
1.52
32,894
-
Mar 29, 2024
gikakis nicolas
sold (taxes)
-3,282
1.68
-1,954
-
Mar 29, 2024
shah chetan
sold (taxes)
-1,953
1.68
-1,163
-
Mar 29, 2024
broenniman edward g
sold (taxes)
-1,953
1.68
-1,163
-
Dec 29, 2023
gikakis nicolas
sold (taxes)
-4,279
2.19
-1,954
-
Dec 29, 2023
shah chetan
sold (taxes)
-2,546
2.19
-1,163
-
Dec 29, 2023
broenniman edward g
sold (taxes)
-2,546
2.19
-1,163
-

1–10 of 50

Which funds bought or sold AEMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
MORGAN STANLEY
unchanged
-
-45.00
150
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
5.28
-455
1,910
-%
May 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
unchanged
-
-10,340
34,060
-%
May 13, 2024
UBS Group AG
added
119
91.00
225
-%
May 10, 2024
GROUP ONE TRADING, L.P.
reduced
-7.66
-841
2,045
-%
May 10, 2024
VANGUARD GROUP INC
unchanged
-
-10,825
35,656
-%
May 10, 2024
BlackRock Inc.
unchanged
-
-3,744
12,331
-%
May 10, 2024
OSAIC HOLDINGS, INC.
unchanged
-
-151
501
-%
May 10, 2024
WELLS FARGO & COMPANY/MN
unchanged
-
-118
386
-%
May 09, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
unchanged
-
-13.00
44.00
-%

1–10 of 17

Are Funds Buying or Selling AEMD?

Are funds buying AEMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AEMD
No. of Funds

Unveiling Aethlon Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 13, 2022
empery asset management, lp
0.68%
105,000
SC 13G/A
Jun 15, 2021
empery asset management, lp
9.82%
1,388,079
SC 13G
Feb 22, 2021
iroquois capital management, llc
0.86%
104,572
SC 13G/A
Jan 29, 2021
intracoastal capital, llc
1.5%
179,116
SC 13G/A
Jan 13, 2021
empery asset management, lp
4.99%
825,020
SC 13G
Feb 14, 2020
iroquois capital management, llc
6.3%
110,701
SC 13G/A
Feb 11, 2020
intracoastal capital, llc
9.99%
324,082
SC 13G/A
Jan 27, 2020
empery asset management, lp
4.99%
30,545
SC 13G/A
Jan 27, 2020
empery asset management, lp
7.73%
506,700
SC 13G
Jan 24, 2020
armistice capital, llc
3.8%
315,648
SC 13G

Recent SEC filings of Aethlon Medical Inc

View All Filings
Date Filed Form Type Document
May 24, 2024
8-K
Current Report
May 17, 2024
8-K
Current Report
May 16, 2024
EFFECT
EFFECT
May 16, 2024
424B4
Prospectus Filed
May 15, 2024
EFFECT
EFFECT
May 15, 2024
POS AM
POS AM
May 13, 2024
S-1/A
Initial Public Offering
May 10, 2024
CORRESP
CORRESP
May 10, 2024
CORRESP
CORRESP
May 10, 2024
8-K
Current Report

Peers (Alternatives to Aethlon Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.9B
40.3B
0.83% -2.36%
32.67
4.56
-2.84% -3.00%
68.8B
19.7B
1.55% -7.75%
51.62
3.49
4.82% -17.56%
18.2B
3.9B
-7.27% -27.59%
39.43
4.65
5.72% 46.72%
17.5B
14.9B
-0.20% -24.24%
6.59
1.17
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.35% 28.70%
31.09
2.75
6.16% 35.06%
8.6B
12.4B
-7.10% -15.64%
22.19
0.69
-0.93% -18.83%
8.2B
2.6B
-1.46% -21.16%
-25.44
3.15
-6.25% -68.58%
5.3B
3.9B
-9.30% -34.58%
-55.31
1.34
0.23% 90.80%
3.5B
387.1M
0.09% 32.88%
-216.75
8.92
30.82% 65.57%
2.1B
6.6B
-0.78% -22.30%
11.5
0.32
1.50% -10.29%
SMALL-CAP
1.5B
3.2B
13.79% 11.94%
-2.12
0.45
7.94% -1695.32%
386.1M
169.3M
2.48% -2.36%
-5.03
2.28
7.49% -244.90%
235.1M
324.0M
-7.12% -47.35%
-1.22
0.73
-3.19% -337.41%
47.8M
50.5M
-13.75% -80.99%
-2.1
0.95
14.25% -10.06%
1.5M
3.7M
37.21% -84.47%
-0.13
0.41
5.77% 8.23%

Aethlon Medical Inc News

Latest updates
StockTitan21 Jun 202412:09 pm
InvestorPlace06 Jun 202407:00 am

Aethlon Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-41.0%6691,1339779717301,004844968433649583792625656564749610762608748587
Operating Expenses12.3%3,5673,1753,4083,0522,8503,6652,9063,7992,5452,1412,2302,2993,0691,7711,4101,9921,2901,7021,5961,6711,964
  S&GA Expenses15.1%9798511,3088281,0711,5481,0321,0271,112686630573921555409550274342383272215
Interest Expenses------------------11.0072.00--
Net Income-14.2%-3,466-3,034-3,282-2,466-2,849-3,807-2,906-3,784-2,525-2,008-2,098-2,259-2,444-1,771-1,411-1,781-819-1,706-2,067-1,634-2,013
Net Income Margin-7.0%-3.27*-3.05*-3.37*-3.39*-3.76*-4.01*-3.88*-3.95*-3.62*-3.33*-3.23*-2.99*-2.86*--------
Free Cashflow12.0%-2,386-2,710-2,712-2,958-2,102-3,617-2,770-3,311-2,776-1,918-2,110-2,243-2,228--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-18.6%10,43712,82815,80117,50920,72423,04717,13219,41821,91623,87425,86710,66912,67015,05616,42710,3884,6821,2822,9334,1234,951
  Current Assets-21.3%8,24910,48713,30815,09118,17220,50415,89418,15721,21023,56925,54810,35212,32214,75216,09510,0414,3069002,6444,0384,860
    Cash Equivalents-21.7%7,97210,17612,89814,62017,50019,60414,92217,16020,39523,22525,1729,90812,17814,47315,7229,6054,0597862,4923,8284,825
  Net PPE-7.2%1,1141,2001,2841,1441,2121,1394524412542141881611671461501401451256.006.0010.00
Liabilities12.6%2,8252,5092,6922,4453,4453,1792,2122,4271,357--1,3751,2361,4901,2401,1108781,2611,9151,8241,781
  Current Liabilities22.8%2,1011,7111,8221,5052,4362,1011,6451,8241,0709741,1311,3751,2361,4901,2231,0688111,1691,7971,8241,781
Shareholder's Equity-26.2%7,61110,31913,10915,06417,27919,86814,92016,99120,55922,90024,7369,29411,43413,56715,1879,2773,80421.001,0182,2993,170
  Retained Earnings-2.3%-152,141-148,675-145,640-142,358-139,892-137,042-133,234-130,329-126,544-124,018-122,010-119,913-117,650-115,207-113,436-112,026-110,243-109,423-107,718-105,652-104,010
  Additional Paid-In Capital0.5%159,752159,002158,732157,427157,148156,888148,281147,447147,229147,042146,869129,332129,207128,896128,745121,427114,173109,572108,845108,076107,284
Shares Outstanding4.2%2,5972,4932,4842,2992,2952,0751,5491,5421,4541,4111,2831,5421,209--------
Minority Interest--------142-141-141-138-138-136-135-133-132-132-129-128-126-126-122
Float------13,200---58,900---16,200---4,500---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations12.1%-2,377-2,704-2,482-2,946-1,951-2,878-2,728-3,099-2,718-1,878-2,071-2,238-2,197-1,226-1,101-1,620-1,256-1,073-1,247-1,397-1,086
  Share Based Compensation122.8%57325725026026331421522820120112015037816784.0088.00103327327374345
Cashflow From Investing-30.1%-8.81-6.77-230-11.29-151-739-41.17-212-57.93-40.49-38.37-5.25-31.49-5.33-17.81-3.60-28.08-119-886*--
Cashflow From Financing1899.5%177-9.841,078-2.64-1.888,300619-10.64-13.56-28.1317,420-26.14-66.01-16.137,2377,1704,557-514-87.15401833
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AEMD Income Statement

2023-12-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
OPERATING EXPENSES    
Professional fees$ 668,586$ 729,665$ 2,778,335$ 2,575,496
Payroll and related expenses1,919,3051,048,7614,233,9703,191,402
General and administrative979,1971,071,3273,138,2893,653,832
Total operating expenses3,567,0882,849,75310,150,5949,420,730
OPERATING LOSS(3,567,088)(2,849,753)(10,150,594)(9,420,730)
OTHER EXPENSE/(INCOME)    
Loss on dissolution of subsidiary000142,121
Interest and Other Income(100,967)0(367,838)0
NET LOSS(3,466,121)(2,849,753)(9,782,756)(9,562,851)
OTHER COMPREHENSIVE INCOME7,95104,5220
COMPREHENSIVE LOSS$ (3,458,170)$ (2,849,753)$ (9,778,234)$ (9,562,851)

AEMD Balance Sheet

2023-12-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2023
Mar. 31, 2023
Current assets  
Cash$ 7,972,012$ 14,532,943
Prepaid expenses and other current assets277,321557,623
Total current assets8,249,33315,090,566
Property and equipment, net1,113,8801,144,004
Right-of-use lease asset, net951,4661,151,909
Patents, net1,2381,650
Restricted cash87,50687,506
Deposits33,30533,305
Total assets10,436,72817,508,940
Current liabilities  
Accounts payable693,154432,890
Due to related parties656,045214,221
Lease liability, current portion285,095269,386
Other current liabilities466,329588,592
Total current liabilities2,100,6231,505,089
Lease liability, less current portion724,848939,642
Total liabilities2,825,4712,444,731
Stockholders’ Equity  
Common stock, par value $0.001 per share; 60,000,000 shares authorized as of December 31, 2023 and March 31, 2023; 2,596,538 and 2,299,259 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively2,5962,299
Additional paid-in capital159,751,591157,426,606
Accumulated other comprehensive loss(1,619)(6,141)
Accumulated deficit(152,141,311)(142,358,555)
Total stockholders’ equity7,611,25715,064,209
Total liabilities and stockholders’ equity$ 10,436,728$ 17,508,940
AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
 CEO
 WEBSITEaethlonmedical.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES15

Aethlon Medical Inc Frequently Asked Questions


What is the ticker symbol for Aethlon Medical Inc? What does AEMD stand for in stocks?

AEMD is the stock ticker symbol of Aethlon Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aethlon Medical Inc (AEMD)?

As of Fri Jun 21 2024, market cap of Aethlon Medical Inc is 1.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers. The fair value of Aethlon Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aethlon Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AEMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aethlon Medical Inc a good stock to buy?

The fair value guage provides a quick view whether AEMD is over valued or under valued. Whether Aethlon Medical Inc is cheap or expensive depends on the assumptions which impact Aethlon Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AEMD.

What is Aethlon Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, AEMD's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 0.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AEMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aethlon Medical Inc's stock?

In the past 10 years, Aethlon Medical Inc has provided -0.533 (multiply by 100 for percentage) rate of return.